Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$625.65 USD

625.65
14,103,382

-15.21 (-2.37%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $626.40 +0.75 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (68 out of 244)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teva (TEVA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

Zacks Equity Research

Merck (MRK) Beats on Q3 Earnings, Lags Sales, Ups EPS View

by Zacks Equity Research

Merck (MRK) beat estimates for earnings while missing the same for sales in third-quarter 2018. Blockbuster cancer drug, Keytruda continues its robust performance on strong demand trends.

Zacks Equity Research

J&J Intends to Buy Residual Stake in Japanese Skincare Firm

by Zacks Equity Research

Johnson & Johnson (JNJ) makes a tender offer to buy the leftover stake in Japanese skincare firm Ci:z Holdings for about $2.05 billion in cash to strengthen its dermatology portfolio.

Zacks Equity Research

Incyte (INCY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors are looking forward to Jakafi's performance and other pipeline updates when Incyte (INCY) reports Q3 results on Oct 30.

Zacks Equity Research

Pfizer Succeeds in Pain Study, Forms JV to Make CNS Drugs

by Zacks Equity Research

Pfizer (PFE) and Lilly present detailed data from a phase III study on pain candidate, tanezumab. The former forms a new company for CNS treatment in alliance with Bain Capital.

Zacks Equity Research

Alkermes Boasts Strong Portfolio and Impressive Pipeline

by Zacks Equity Research

Alkermes (ALKS) has a strong product portfolio, including a number of pipeline candidates with significant potential.

    Zacks Equity Research

    BMY vs. LLY: Which Stock Should Value Investors Buy Now?

    by Zacks Equity Research

    BMY vs. LLY: Which Stock Is the Better Value Option?

    Zacks Equity Research

    Puma Biotech (PBYI) Rides High on Robust Nerlynx Performance

    by Zacks Equity Research

    Puma Biotech (PBYI) focuses on improving sales of its flagship and the only approved product Nerlynx. The drug's label expansion programs also appear promising.

      Zacks Equity Research

      Novo Nordisk (NVO) Faces Pricing Pressure and Competition

      by Zacks Equity Research

      Novo Nordisk (NVO) faces pricing pressures and intense competition in the Diabetes market.

        Zacks Equity Research

        Can Allergan's Key Drugs, Solid Pipeline Abate Generic Woes?

        by Zacks Equity Research

        Allergan (AGN) is facing loss of exclusivity for many blockbuster products. However, drugs like Botox/Linzess, new drugs and cost cuts can shield it from potential sales drop.

        Zacks Equity Research

        AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status

        by Zacks Equity Research

        AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.

          Zacks Equity Research

          Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal

          by Zacks Equity Research

          AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.

          Zacks Equity Research

          3 Large-Cap Pharma Stocks Performing Better Than Industry

          by Zacks Equity Research

          We focus on three large-cap pharma stocks that are outperforming the industry on the back of their diverse portfolio.

          Zacks Equity Research

          Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?

          by Zacks Equity Research

          Is (LLY) Outperforming Other Medical Stocks This Year?

          Zacks Equity Research

          This is Why Eli Lilly (LLY) is a Great Dividend Stock

          by Zacks Equity Research

          Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.

          Zacks Equity Research

          Incyte's Jakafi Demand Strong, Label Expansion to Boost Sales

          by Zacks Equity Research

          Incyte's (INCY) performance is likely to be strong due to rising demand of lead drug, Jakafi.

          Sweta Killa headshot

          Is Franklin LibertyQ U.S. Equity ETF (FLQL) a Hot ETF Right Now?

          by Sweta Killa

          Smart Beta ETF report for FLQL

          Zacks Equity Research

          Company News For Oct 5, 2018

          by Zacks Equity Research

          Companies In The News are: CLDR,HDP,BKS,LLLY,STZ

            Zacks Equity Research

            Pharma Stock Roundup: PFE to Get New CEO, LLY Presents Impressive Diabetes Data

            by Zacks Equity Research

            Pfizer (PFE) CEO, Ian Read to be replaced by present chief operating officer. Pipeline updates from Lilly (LLY), Novartis (NVS), J&J (JNJ) and others.

              Zacks Equity Research

              Lilly's Novel Diabetes Candidate Shows Promise in Phase II

              by Zacks Equity Research

              Lilly's (LLY) dual GIP and GLP-1 receptor agonist demonstrates impressive reduction in blood sugar levels as well as body weight in type II diabetes patients.

              Kevin Cook headshot

              Bull of the Day: Roche (RHHBY)

              by Kevin Cook

              With 3 of the top-ten cancer drugs globally, this Swiss giant is looking for the next I/O breakthroughs

                Zacks Equity Research

                Eli Lilly's Ultra Rapid Lispro Succeeds in Diabetes Studies

                by Zacks Equity Research

                Eli Lilly's (LLY) insulin candidate, Ultra Rapid Lispro, meets primary endpoint of two late- stage studies in type I and type II diabetes patients of non-inferiorly to Humalog.

                  Kinjel Shah headshot

                  Merck & Other Pharma Players Await FDA Decisions in October

                  by Kinjel Shah

                  FDA grants approval to 41 new treatments till the end of September.

                    Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical

                    by Zacks Equity Research

                    The Zacks Analyst Blog Highlights: Alphabet, Bank of America, PepsiCo, Eli Lilly and Intuitive Surgical

                      Zacks Equity Research

                      Eli Lilly (LLY) Gets FDA Nod for Migraine Drug Emgality

                      by Zacks Equity Research

                      Eli Lilly's (LLY) CGRP antibody Emgality injection gains an FDA approval for the preventive treatment of migraine in adults.